Jazz Pharmaceuticals plc (JAZZ) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Jazz Pharmaceuticals financial statements at a glance

Jazz Pharmaceuticals reported revenue of $4.27 billion for fiscal year 2025 (ended December 31, 2025), up 4.9% from fiscal year 2024. Net income was -$356.15 million, a net margin of 8.3% loss, and diluted earnings per share were -$5.84.

At the end of fiscal year 2025 it had total assets of $11.66 billion, total liabilities of $7.34 billion and shareholders' equity of $4.32 billion, with cash and short-term investments of $2.44 billion and total debt of $5.42 billion.

Its operations brought in $1.36 billion of cash; capital spending was $209.75 million, leaving free cash flow of $1.15 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

JAZZ logo

Jazz Pharmaceuticals plc

JAZZIreland
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
4.27B
Prev Year: 4.07B
YoY: +4.9%
Operating Revenue
4.27B
Prev Year: 4.07B
YoY: +4.9%
Total Unusual Items
-950.43M
Prev Year: -18.18M
YoY: -5127.3%
Total Unusual Items Excluding Goodwill
-950.43M
Prev Year: -18.18M
YoY: -5127.3%
Total Expenses
3.75B
Prev Year: 3.34B
YoY: +12.2%
Total Operating Income as Reported
-430.24M
Prev Year: 716.63M
YoY: -160.0%
Diluted NI Available to Com Stockholders
-356.15M
Prev Year: 570.88M
YoY: -162.4%
Equity in Earnings of Affiliates, Net of Tax
-732.0K
Prev Year: -1.66M
YoY: +55.9%
Special Income Charges
-947.86M
Prev Year: -10.00M
YoY: -9378.6%
Other Special Charges
947.86M
Prev Year: 10.00M
YoY: +9378.6%
Gain on Sale of Securities
-2.57M
Prev Year: -8.18M
YoY: +68.6%
Cost of Revenue
503.30M
Prev Year: 445.71M
YoY: +12.9%
Gross Profit
3.76B
Prev Year: 3.62B
YoY: +3.9%
Operating Expense
3.25B
Prev Year: 2.90B
YoY: +12.1%
Selling General and Administrative
1.81B
Prev Year: 1.39B
YoY: +30.6%
Research and Development
782.74M
Prev Year: 884.00M
YoY: -11.5%
Depreciation Amortization Depletion
654.66M
Prev Year: 627.31M
YoY: +4.4%
Depreciation and amortization
654.66M
Prev Year: 627.31M
YoY: +4.4%
Amortization
654.66M
Prev Year: 627.31M
YoY: +4.4%
Amortization of Intangibles
654.66M
Prev Year: 627.31M
YoY: +4.4%
Operating Income
517.62M
Prev Year: 726.63M
YoY: -28.8%
Net Non Operating Interest Income Expense
-195.05M
Prev Year: -238.10M
YoY: +18.1%
Non-operating Interest Expense
195.05M
Prev Year: 238.10M
YoY: -18.1%
Other Income Expense
-950.43M
Prev Year: -18.18M
YoY: -5127.3%
Pre-tax Income
-627.86M
Prev Year: 470.35M
YoY: -233.5%
Provision for Income Taxes
-272.44M
Prev Year: -91.43M
YoY: -198.0%
Net Income Common Stockholders
-356.15M
Prev Year: 560.12M
YoY: -163.6%
Net Income
-356.15M
Prev Year: 560.12M
YoY: -163.6%
Net Income Including Non-Controlling Interests
-356.15M
Prev Year: 560.12M
YoY: -163.6%
Net Income from Continuing Operations
-356.15M
Prev Year: 560.12M
YoY: -163.6%
Basic EPS
-5.84
Prev Year: 9.06
YoY: -164.5%
Diluted EPS
-5.84
Prev Year: 8.65
YoY: -167.5%
Weighted Average Shares (basic)
60.98M
Prev Year: 61.84M
YoY: -1.4%
Weighted Average Shares (diluted)
60.98M
Prev Year: 66.01M
YoY: -7.6%
Net Income from Continuing and Discontinued Operation
-356.15M
Prev Year: 560.12M
YoY: -163.6%
Normalized Income
394.69M
Prev Year: 574.48M
YoY: -31.3%
Interest Expense
195.05M
Prev Year: 238.10M
YoY: -18.1%
Net Interest Income
-195.05M
Prev Year: -238.10M
YoY: +18.1%
EBIT
-432.81M
Prev Year: 708.45M
YoY: -161.1%
EBITDA
263.49M
Prev Year: 1.37B
YoY: -80.7%
Reconciled Cost of Revenue
461.66M
Prev Year: 412.96M
YoY: +11.8%
Reconciled Depreciation
696.30M
Prev Year: 660.07M
YoY: +5.5%
Net Income from Continuing Operation Net Minority Interest
-356.15M
Prev Year: 560.12M
YoY: -163.6%
Normalized EBITDA
1.21B
Prev Year: 1.39B
YoY: -12.5%
Tax Rate for Calcs
0.21
Prev Year: 0
Tax Effect of Unusual Items
-199.59M
Prev Year: -3.82M
YoY: -5127.3%
Values in USD

Jazz Pharmaceuticals key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$4.3B$4.1B$3.8B$3.7B$3.1B
Gross profit$3.8B$3.6B$3.4B$3.1B$2.7B
Operating income$517.6M$726.6M$597.6M$512.3M$170.3M
Net income-$356.1M$560.1M$414.8M-$224.1M-$329.7M
Diluted EPS-$5.84$8.65$6.10-$3.58-$5.52
Total assets$11.7B$12.0B$11.4B$10.8B$12.3B
Total liabilities$7.3B$7.9B$7.7B$7.7B$8.3B
Shareholders' equity$4.3B$4.1B$3.7B$3.1B$4.0B
Cash and short-term investments$2.4B$3.0B$1.6B$881.5M$591.4M
Total debt$5.4B$6.2B$5.8B$5.8B$6.2B
Operating cash flow$1.4B$1.4B$1.1B$1.3B$778.5M
Capital spending$209.8M$48.1M$43.0M$498.2M$45.5M
Free cash flow$1.1B$1.3B$1.0B$773.8M$733.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Jazz Pharmaceuticals's revenue in fiscal year 2025?

$4.27 billion, up 4.9% from $4.07 billion in fiscal year 2024.

How much profit does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals reported net income of -$356.15 million for fiscal year 2025 (8.3% of revenue); operating income was $517.62 million.

How much cash and debt does Jazz Pharmaceuticals have?

At the end of fiscal year 2025: cash and short-term investments of $2.44 billion and total debt of $5.42 billion.

What is Jazz Pharmaceuticals's free cash flow?

$1.15 billion in fiscal year 2025 (operating cash flow of $1.36 billion minus capital spending of $209.75 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube